All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Why are novel TKIs needed for Ph+ ALL? What does this mean for patients?

During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Jorge Cortes, Augusta University, Augusta, US. We asked, Why are novel TKIs needed for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)? What does this mean for patients?

Why are novel TKIs needed for Ph+ ALL? What does this mean for patients?

Cortes begins by explaining that despite a dramatic evolution in treatment, risks and outcomes for many patients can still improve. Cortes highlights hopes for better quality of life, higher cure rate, fewer toxicities, and reduced need for stem cell transplants. Finally, he discusses prospects for patients with Ph+ ALL.

 

Share: